

In the Claims:

Please amend the claims as follows:

1. (Currently Amended) A composition comprising *ex vivo* expanded CIK cells (defined as TH1 activated, non-MHC restricted cytotoxic T cells), wherein at least 2% of the expanded CIK cells are at least 2-fold more selective for cells that selectively damage damaging tumor-associated vasculatur cells compared to unstimulated PBMC cells compared to normal vasculature and a pharmaceutically acceptable carrier.

2. (Canceled).

3. (Original) The composition of claim 1 wherein the selectivity is at least 5-fold.

4. (Original) The composition of claim 1 wherein the selectivity is at least 100-fold.

5. (Canceled).

6. (Currently Amended) The composition of claim 1 5 wherein at least 5% of the *ex vivo* expanded CIK cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

7. (Currently Amended) The composition of claim 6 wherein at least 10% of the *ex vivo* expanded CIK cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

8. (Currently Amended) The composition of claim 6 wherein at least 50% of the *ex vivo* CIK expanded cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

9-13. (Canceled).

Scope
only used
HUVEC
how do you
screen for
tumor specific
clones?

14. (Original) The composition of claim 12 or 13 wherein the antigen recognition is non-classical MHC restricted.



15. (Original) The composition of claim 12 or 13 wherein the antigen recognition is MHC-independent.

16. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes heat shock protein 47 (Hsp47).

17. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes HLA.

18. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes IL-12 receptor ~~or a part thereof~~.

19. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes a heat shock protein.

20. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells comprise cells expressing both CD3 and CD56.

21. (Original) The composition of claim 1 wherein the ex vivo expanded cells comprise cells that kill tumor cells.

22. (Original) The composition of claim 1 further comprising a chemotherapeutic compound.

23. (Canceled).

24. (Original) The composition of claim 1 wherein an agent binds to the ex vivo expanded cell non-covalently.

B1
cut

25. (Amended) The composition of claim 24 wherein the agent is a mono-, bi- or multi-specific antibody or molecular scaffold, directed with at least one binding activity to the CIK cell, and at least one other domain against a cancer cell or endothelial target.

26-59. (Canceled).

60. (New) A composition comprising *ex vivo* expanded CIK cells wherein at least 2% of the *ex vivo* expanded CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47 and a pharmaceutically acceptable carrier.

B1
nd
61. (New) The composition of claim 60 wherein at least 5% of the *ex vivo* expanded CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47.

62. (New) The composition of claim 60 wherein at least 10% of the CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47.

63. (New) The composition of claim 60 wherein at least 50% of the CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47.
